Alison Johnson

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 214 citations

Gortec 2014-01 Tpextreme, Neoadjuvant Therapy, Medicine +11

Gamma-probe-guided resection of the sentinel lymph node in breast cancer.

J A Crossin, Alison Johnson, Philippa Stewart et al. · PubMed · 1998 · 90 citations

Surgical Oncology, Sentinel Lymph Nodes, Breast Oncology +13

Effect of a Commercial Competitive Exclusion Culture on Reduction of Colonization of an Antibiotic-Resistant Pathogenic Escherichia coli in Day-Old Broiler Chickens

Charles L. Hofacre, Alison Johnson, Barry Kelly et al. · Avian Diseases · 2002 · 43 citations

Antimicrobial Resistance Gene, Antimicrobial Susceptibility, Health Sciences +15

NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.

Jean Bourhis, Anne Aupérin, Christian Borel et al. · Journal of Clinical Oncology · 2025 · 36 citations

Surgical Oncology, Neoadjuvant Therapy, Lba2 Background +21

TPExtreme randomized trial: Quality of Life (QoL) and survival according to second-line treatments in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

J. Guigay, Jérôme Fayette, Esma Saâda-Bouzid et al. · Journal of Clinical Oncology · 2020 · 24 citations

Extreme Regimen, Cancer Management, Immunology +22